---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-001617"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:32:04.444471+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences reports positive interim Phase 2 data for ART27.13 in cancer cachexia; seeks licensing partner

## Summary
- Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.
- Lean body mass increased +4.23% in treatment group vs -3.15% loss in placebo at one month.
- Safety: 22% of 32 patients had possibly related adverse events, all mild/moderate except one severe malaise; no drug-related serious AEs.
- Company will not internally fund Phase 3; plans to pursue licensing/partnership for ART27.13 as most value-accretive path.

## SEC filing metadata
- accession: 0001640334-25-001617
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/0001640334-25-001617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-001617
- JSON: https://secwatch.observer/filing/0001640334-25-001617.json
- Plain text: https://secwatch.observer/filing/0001640334-25-001617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.